sentences:  Volociximab
  
  Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors.It binds to and inhibits the functional activity of α5β1 integrin.